HCW Biologics/HCWB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About HCW Biologics

HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID-19. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth factor-β and stimulate immune cells, targeting senescent cells and the SASP factors they secrete. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, and others.

Ticker

HCWB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Hing Wong

Employees

45

Headquarters

Miramar, United States

HCW Biologics Metrics

BasicAdvanced
$41M
Market cap
-
P/E ratio
-$0.75
EPS
-
Beta
-
Dividend rate
$41M
$2.32
$0.91
19K
0.463
94.667
94.667
-146.89%
-74.07%
-132.46%
-97.78%
10.499
4.717
4.717
7.68%
-51.03%
-11.50%

What the Analysts think about HCW Biologics

Analyst Ratings

Majority rating from 1 analysts.
Buy

HCW Biologics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-672.72% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.1M
-15.38%
Net income
-$7.4M
-30.19%
Profit margin
-672.72%
-17.50%

HCW Biologics Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 114.29%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.14
-$0.12
-$0.14
-$0.30
Expected
-$0.14
-$0.15
-$0.13
-$0.14
Surprise
0.00%
-18.18%
7.69%
114.29%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for HCW Biologics stock?

HCW Biologics (HCWB) has a market cap of $41M as of June 17, 2024.

What is the P/E ratio for HCW Biologics stock?

The price to earnings (P/E) ratio for HCW Biologics (HCWB) stock is 0 as of June 17, 2024.

Does HCW Biologics stock pay dividends?

No, HCW Biologics (HCWB) stock does not pay dividends to its shareholders as of June 17, 2024.

When is the next HCW Biologics dividend payment date?

HCW Biologics (HCWB) stock does not pay dividends to its shareholders.

What is the beta indicator for HCW Biologics?

HCW Biologics (HCWB) does not currently have a Beta indicator.

What is the HCW Biologics stock price target?

The target price for HCW Biologics (HCWB) stock is $4, which is NaN% below the current price of $. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell HCW Biologics stock

Buy or sell HCW Biologics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing